Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2017

View Archived Issues

Halozyme Therapeutics begins trial of PEGPH20 plus atezolizumab

NIH grant supports Crinetics' development of CRN-00808 for acromegaly

Roche and Genentech patent JAK inhibitors

Bayer discloses TBK1 and IKK-E inhibitors

Sichuan Haisco Pharmaceutical divulges CACNA2D1 ligands

EMBL and Savira Pharmaceuticals discover compounds for treating influenza

GlaxoSmithKline patents RIP-1 inhibitors

Amgen files to add OS data from ENDEAVOR to Kyprolis label in U.S. and E.U.

VSIG4 g.18115T allele tied to rheumatoid arthritis severity in females

Prima BioMed to receive second milestone payment from IMP-701 collaboration with Novartis

New phase I trial evaluates MK-1308 with pembrolizumab in advanced solid tumors

Emergent BioSolutions agrees to acquire Sanofi's ACAM2000 business

FDA grants orphan drug designation to NanoCarrier's epirubicin-conjugated polymer micelles

IL-13RA2 found as a therapeutic target for treating IBD

FDA issues complete response letter for Evenity for postmenopausal osteoporosis

FDA awards orphan drug designation to liposomal vinorelbine for soft tissue carcinoma

WOL-074-029, a novel KdPT analogue, shows anti-inflammatory properties with topical application

Merck & Co. divulges HIV integrase inhibitors

EMA committee recommends approval of label update for Lixiana

Enterin completes series A financing to help advance trial of ENT-01

Asterias completes dosing in AIS-A 20 million cell cohort in SCiStar study of AST-OPC1

Dosing begins in phase Ib/II trial of APX-005M with Opdivo in advanced solid tumors

Ionis earns milestone under neurological collaboration with Biogen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...